Searched for
DIABETES IN AMERICA
These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsIn just a few days, the Q1 earnings season for FY27 will start. But before that will come the season of business updates. And that needs to...- For investors looking beyond the short-term horizon: 5 mid-cap stocks from different sectors with upside potential up to 28%All is once again quiet on the US-Iran war front, and some kind of dialogue to resolve the issues between the two seems to be still underwa...
- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Cipla Q4 Results: Profit falls 55% YoY to Rs 555 crore; co declares Rs 13/sh dividendCipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Wealth creation is also about ignoring noise on the street: 15 mid- and small-cap stocks from different sectors which fit the billIn the April 2022-September 2024 bull market, every management appeared capable. Margins expanded, working capital looked manageable, capit...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- International travel insurance: How to choose right cover with adequate medical protection, add-ons and claims supportMedical coverage, duration and geography, add-ons, and claims experience are some aspects one must keep in mind before selecting the intern...
- New Study reveals nearly half of people with Diabetes remain undiagnosed, here’s how to detect earlyA new study published in The Lancet: Diabetes and Endocrinology offers one of the most extensive global evaluations of diabetes care, analy...
- Catching heart disease in its quietest moments in Type 2 diabetesEarly detection of heart disease in Type 2 diabetes is crucial, as it often develops silently. Advanced tests like high-sensitivity blood w...
- Americans' favourite comfort food they eat every day could spike diabetes by 20 percent: Harvard studyA Harvard study revealed that frequent consumption of French fries significantly elevates the risk of type 2 diabetes, while other potato p...
- Lupin inks licensing deal to supply biosimilar ranibizumab in Latin AmericaLupin, an Indian drug maker, partners with SteinCares. The agreement focuses on ranibizumab's commercialisation. Latin America, excluding M...
- Non-Covid deaths increased in people with diabetes, women, young affected more: Lancet StudyThe team of researchers, including those from the World Health Organization (WHO), looked at 138 studies - North America (39), Western Euro...
- Keeros Foods plans to raise $4 million over next two yearsKeeros Foods, a maker of diabetes snacks, plans to expand its reach to Top 30 cities in India, in an effort to tap the country’s $600-milli...
Load More
